Skip to search formSkip to main contentSkip to account menu

HL156A

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

GuanidinesPyrrolidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Metabolic Reprogramming by the Excessive AMPK Activation Exacerbates Antigen-Specific Memory CD8+ T Cell Differentiation after Acute Lymphocytic Choriomeningitis Virus Infection
During virus infection, T cells must be adapted to activation and lineage differentiation states via metabolic reprogramming… 
2018
2018
New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin‐like growth factor/AKT/mammalian target of rapamycin pathways
Metformin is a biguanide widely prescribed as an antidiabetic drug for type 2 diabetes mellitus patients. The purpose of the… 
2018
2018
Antioxidant modifications induced by the new metformin derivative HL156A regulate metabolic reprogramming in SAMP1/kl (-/-) mice
Aging is characterized by a reduced ability to defend against stress, an inability to maintain homeostasis, and an increased risk… 
2018
2018
HL156A, a novel pharmacological agent with potent adenosine-monophosphate-activated protein kinase (AMPK) activator activity ameliorates renal fibrosis in a rat unilateral ureteral obstruction model
Background Renal fibrosis is characterized by excessive production and deposition of extracellular matrix (ECM), which leads to… 
2016
2016
Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A)
Studies have investigated biguanide-derived agents for the treatment of cancers and have reported their effects against… 
2016
2016
HL156A, a novel AMP-activated protein kinase activator, is protective against peritoneal fibrosis in an in vivo and in vitro model of peritoneal fibrosis.
HL156A is a novel AMP-activated protein kinase (AMPK) activator. We aimed to investigate the protective mechanism of HL156A… 
2016
2016
AMP-activated protein kinase activator, HL156A reduces thioacetamide-induced liver fibrosis in mice and inhibits the activation of cultured hepatic stellate cells and macrophages.
Cirrhosis, the end-stage of hepatic fibrosis, is not only life-threatening by itself, but also a causative factor of liver cancer… 
2016
2016
AMP-activated protein kinase activator , HL 156 A reduces thioacetamide-induced liver fibrosis in mice and inhibits the activation of cultured hepatic stellate cells and macrophages
Cirrhosis, the end-stage of hepatic fibrosis, is not only life-threatening by itself, but also a causative factor of liver cancer… 
2015
2015
HL 156 A , a novel AMP-activated protein kinase activator , is protective 3 against peritoneal fibrosis in an in-vivo and in-vitro model of peritoneal 4 fibrosis 5 6
45 HL156A is a novel adenosine5’-monophosphate-activated protein kinase (AMPK) activator. We 46 aimed to investigate the… 
2008
2008
The AMPK activators, HL156A and HL176OUT04 reduce thioacetamide-induced hepatic fibrosis via the inhibition of hepatic stellate cell activation AMPK
.......................................................................1 LIST OF FIGURES… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License